{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:58:51Z","timestamp":1792277931876,"version":"4.4.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Extraintestinal manifestations (EIMs) are commonly observed in patients with Crohn\u2019s disease (CD). Although Tumor Necrosis Factor (TNF) antagonists are commonly recommended for the management of several EIMs, their efficacy remains limited. Ustekinumab (UST), an alternative option after TNF antagonists failure, has shown potential efficacy for various EIMs. However, evidence regarding its effectiveness remains inconsistent. This study aimed to evaluate the efficacy and safety of UST and TNF antagonists for CD-related EIMs through a systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, and Cochrane Library were searched on 2 August 2025, to identify phase II and III randomized controlled trials (RCTs) evaluating UST or TNF antagonists in adults aged \u226518 years with moderate-to-severe active CD. The primary outcomes were EIMs and EIM-related symptoms. Two investigators, adhering to the PRISMA guidelines, independently screened the literature and extracted data. The risk of bias was assessed using the Cochrane Risk-of-Bias Tool 2.0. Random-effects and fixed-effect models were used to estimate pooled treatment effects. Results were presented using risk ratios (RRs), incidence rate ratios (IRRs) and 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 23 RCTs, involving 7,810 patients, were included, with EIMs such as fatigue, joint pain, and skin manifestations being considered. The meta-analysis revealed that UST significantly reduced the risk of fatigue in CD patients (IRR 0.53, 95% CI 0.33\u20130.84, P = 0.008). During maintenance therapy, UST treatment was significantly associated with a reduction in the risk of arthritis\/arthralgia (IRR 0.56, 95% CI 0.36\u20130.86, P = 0.008). Weekly adalimumab (ADA) treatment was significantly associated with an increased risk of fatigue (IRR 2.79, 95% CI 1.12\u20136.94, P = 0.028).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>UST showed potential advantages in the management of fatigue and arthritis\/arthralgia. ADA and infliximab (IFX) were not associated with statistically significant benefits for most analyzed EIM outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251111502<\/jats:ext-link>\n                      , identifier CRD420251111502.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1849397","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:20:55Z","timestamp":1785385255000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of ustekinumab and tumor necrosis factor antagonists on extraintestinal manifestations of Crohn\u2019s disease: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Mao-xuan","family":"Lin","sequence":"first","affiliation":[{"name":"Third Affiliated Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu-nan","family":"Ding","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo-han","family":"Sun","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-yu","family":"Dong","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-qing","family":"Zheng","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-wen","family":"Hu","sequence":"additional","affiliation":[{"name":"Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-dong","family":"Yu","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-fu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tsinghua University Yuquan Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[{"name":"Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","article-title":"Infliximab-abda","volume-title":"Statpearls.","author":"Aboobacker","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nri1784","article-title":"Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease","volume":"6","author":"Adams","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40259-020-00451-w","article-title":"Clinical trials of IL-12\/IL-23 inhibitors in inflammatory bowel disease","volume":"34","author":"Almradi","year":"2020","journal-title":"BioDrugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e83491","DOI":"10.7759\/cureus.83491","article-title":"Anti-tumor necrosis factor-alpha (TNF-\u03b1)-Induced hypertrophic lichen planus: a case report","volume":"17","author":"Alqefari","year":"2025","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohns disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/ecco-jcc\/jjz148","article-title":"Longitudinal trajectory of fatigue with initiation of biologic therapy in inflammatory bowel diseases: a prospective cohort study","volume":"14","author":"Borren","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/annrheumdis-2016-211064","article-title":"Faecal microbiota study reveals specific dysbiosis in spondyloarthritis","volume":"76","author":"Breban","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/1479-5876-10-191","article-title":"Cytokine expression profiles of immune imbalance in post-mononucleosis chronic fatigue","volume":"10","author":"Broderick","year":"2012","journal-title":"J. Transl. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1611720","DOI":"10.3389\/pore.2024.1611720","article-title":"Case report: effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol","volume":"30","author":"Cegl\u00e9di","year":"2024","journal-title":"Pathol. Oncol. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2058738419866567","DOI":"10.1177\/2058738419866567","article-title":"Inflammatory bowel disease: looking beyond the tract","volume":"33","author":"Chams","year":"2019","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1756284820938960","DOI":"10.1177\/1756284820938960","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderately to severely active crohn's disease: results from a randomized trial","volume":"13","author":"Chen","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"17562848251375844","DOI":"10.1177\/17562848251375844","article-title":"Efficacy and safety of risankizumab for moderate-to-severe crohn's disease: first Asian real-world data (STAR trial)","volume":"18","author":"Chung","year":"2025","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.tins.2013.10.003","article-title":"The neuroimmune basis of fatigue","volume":"37","author":"Dantzer","year":"2014","journal-title":"Trends Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/ecco-jcc\/jjac058","article-title":"The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentre cohort study","volume":"16","author":"De Galan","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn's disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.31138\/mjr.32.2.96","article-title":"Biologic therapies and autoimmune phenomena","volume":"32","author":"Drosos","year":"2021","journal-title":"Mediterr. J. Rheumatol."},{"key":"B21","article-title":"Adalimumab","volume-title":"Statpearls.","author":"Ellis","year":"2023"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40744-022-00437-w","article-title":"Responding to and driving change in rheumatology: report from the 12th international immunology summit 2021","volume":"9","author":"Felten","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/096228029300200202","article-title":"The statistical basis of meta-analysis","volume":"2","author":"Fleiss","year":"1993","journal-title":"Stat. Methods Med. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/clinpract15030057","article-title":"Pyoderma gangrenosum in a patient with crohn's disease treated with adalimumab: a case-based review and systematic review of the current literature","volume":"15","author":"Fousekis","year":"2025","journal-title":"Clin. Pract."},{"key":"B27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","author":"Garcovich","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10067-013-2469-y","article-title":"Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results","volume":"33","author":"Gheita","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3390\/medicina60091409","article-title":"Neurological side effects of TNF-\u03b1 inhibitors revisited: a review of case reports","volume":"60","author":"Gogulescu","year":"2024","journal-title":"Med. Kaunas."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in crohn's disease: medical treatment","volume":"18","author":"Gordon","year":"","journal-title":"J. Crohns Colitis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"","journal-title":"J. Crohns Colitis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e70029","DOI":"10.1111\/sji.70029","article-title":"Fatigue in inflammatory bowel disease: no effect of serum concentrations of infliximab, adalimumab or anti-drug antibodies during maintenance therapy","volume":"101","author":"Grimstad","year":"2025","journal-title":"Scand. J. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/ecco-jcc\/jjaa260","article-title":"Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review","volume":"15","author":"Guillo","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347","article-title":"GRADE working group. Grade: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst. Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s0149-7634(88)80004-6","article-title":"Biological basis of the behavior of sick animals","volume":"12","author":"Hart","year":"1988","journal-title":"Neurosci. Biobehav Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"B42","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":""},{"key":"B43","article-title":"Chapter 8: assessing risk of bias in a randomized trial","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":""},{"key":"B44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bbi.2007.07.013","article-title":"Human psychoneuroimmunology: 20 years of discovery","volume":"22","author":"Irwin","year":"2008","journal-title":"Brain Behav. Immun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1031998","DOI":"10.3389\/fmed.2023.1031998","article-title":"Personalize, participate, predict, and prevent: 4ps in inflammatory bowel disease","volume":"10","author":"Lenti","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"B48","article-title":"Chapter 5: collecting data","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5","author":"Li","year":"2024"},{"key":"B49","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/ueg2.12420","article-title":"How many biomarker measurements are needed to predict prognosis in crohn's disease patients under infliximab? A prospective study","volume":"11","author":"Magro","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"B50","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume-title":"Statpearls.","author":"Malik","year":"2023"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.2147\/CCID.S544180","article-title":"Guselkumab in A subset of multifailure patients with hidradenitis suppurativa: real-word evidence from federico II","volume":"18","author":"Martora","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1515\/rir-2024-0006","article-title":"Adalimumab in the management of psoriasis and psoriatic arthritis: results from a Delphi investigation","volume":"5","author":"Matucci-Cerinic","year":"2024","journal-title":"Rheumatol. Immunol. Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5217\/ir.2018.00099","article-title":"Health-related quality of life of patients with inflammatory bowel disease in Singapore","volume":"17","author":"Min Ho","year":"2019","journal-title":"Intest. Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"537","DOI":"10.26402\/jpp.2021.4.05","article-title":"Efficacy of ustekinumab in the treatment of patients with crohn's disease with failure to previous conventional or biologic therapy: a prospective observational real-life study","volume":"72","author":"Miranda","year":"2021","journal-title":"J. Physiol. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1007\/s10620-024-08471-0","article-title":"Postoperative ustekinumab drug levels and disease activity in patients with crohn's disease","volume":"69","author":"Moskow","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J. Exp. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of crohn's disease: a post hoc analysis of the UNITI studies","volume":"9","author":"Narula","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/ecco-jcc\/jjy200","article-title":"Refractory pyoderma gangrenosum in a patient with crohn's disease: complete response to ustekinumab","volume":"13","author":"Nunes","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1053\/j.gastro.2008.10.051","article-title":"Infliximab prevents crohn's disease recurrence after ileal resection","volume":"136","author":"Regueiro","year":"2009","journal-title":"Gastroenterology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1053\/j.gastro.2016.02.072","article-title":"Infliximab reduces endoscopic, but not clinical, recurrence of crohn's disease after ileocolonic resection","volume":"150","author":"Regueiro","year":"2016","journal-title":"Gastroenterology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"jjaf100","DOI":"10.1093\/ecco-jcc\/jjaf100","article-title":"Impact of mirikizumab treatment on fatigue in patients with moderately to severely active crohn's disease: results from the phase 3 VIVID-1 study","volume":"19","author":"Regueiro","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"B65","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00403-025-04300-0","article-title":"Tumor necrosis factor \u03b1 inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature","volume":"317","author":"Reiss-Huss","year":"2025","journal-title":"Arch. Dermatol Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/s0016-5085(99)70332-x","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"","journal-title":"Gut"},{"key":"B70","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"","journal-title":"Ann. Intern Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in crohn's disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11926-012-0277-z","article-title":"Peripheral and central mechanisms of fatigue in inflammatory and noninflammatory rheumatic diseases","volume":"14","author":"Staud","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for crohn's disease. Crohn's disease cA2 study group","volume":"337","author":"Targan","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/ecco-jcc\/jjae002","article-title":"Beyond the gut: a systematic review and meta-analysis of advanced therapies for inflammatory bowel disease-associated extraintestinal manifestations","volume":"18","author":"T\u00edm\u00e1r","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2165\/11638120-000000000-00000","article-title":"Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease","volume":"72","author":"Trikudanathan","year":"2012","journal-title":"Drugs"},{"key":"B79","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1097\/MIB.0000000000000429","article-title":"Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1097\/MIB.0000000000001109","article-title":"Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study","volume":"23","author":"Vavricka","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American college of rheumatology\/spondylitis association of america\/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with crohn's disease","volume":"6","author":"Watanabe","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.crohns.2014.04.012","article-title":"Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe crohn's disease","volume":"8","author":"Watanabe","year":"2014","journal-title":"J. Crohns Colitis"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1849397\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:20:58Z","timestamp":1785385258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1849397\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":84,"alternative-id":["10.3389\/fphar.2026.1849397"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1849397","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1849397"}}